LANDSCAPE: Demographics and Treatment Patterns of Patients With Immune-Mediated Inflammatory Skin Diseases in Italian Clinical Practice

Sponsor
Fondazione ISIDE
Study ID
NCT07336641
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
12 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Conventional Systemic Therapies — DRUG
    Retrospective observation of conventional systemic treatments prescribed in routine clinical practice, including but not limited to methotrexate, cyclosporine, acitretin, and other conventional agents. No drugs are administered as part of this study; treatment data are collected from existing medical records.
  • Biologic Therapies — DRUG
    Retrospective observation of biologic treatments prescribed in routine clinical practice, including but not limited to TNF-α inhibitors, IL-17 inhibitors, IL-23 inhibitors, IL-4/IL-13 inhibitors, and JAK inhibitors. No drugs are administered as part of this study; treatment data are collected from existing medical records.

Study Details

This multicenter retrospective observational registry study will collect existing clinical data from Italian centers to describe epidemiology, treatment patterns, clinical evolution, safety, and comorbidities in patients aged 12 years and older with psoriasis, atopic dermatitis, vitiligo, alopecia areata, or hidradenitis suppurativa.

Key Dates

First listed
Jan 13, 2026
Start date
Jan 31, 2026
Status verified
Jan 2026
Primary completion
May 31, 2026
Completion
Jan 31, 2028

Study Design

Enrollment
20,000 participants (estimated)

Arms

  • Arm: Psoriasis Cohort
    Adult patients (≥18 years) diagnosed with moderate-to-severe psoriasis according to clinical criteria, treated with systemic conventional and/or biologic therapies at participating Italian dermatology centers. No intervention is administered; data are collected retrospectively from medical records.
  • Arm: Atopic Dermatitis Cohort
    Adult patients (≥18 years) diagnosed with moderate-to-severe atopic dermatitis, treated with systemic conventional and/or biologic therapies at participating Italian dermatology centers. No intervention is administered; data are collected retrospectively from medical records.
  • Arm: Alopecia Areata Cohort
    Adult patients (≥18 years) diagnosed with alopecia areata, treated with systemic therapies at participating Italian dermatology centers. No intervention is administered; data are collected retrospectively from medical records.
  • Arm: Vitiligo Cohort
    Adult patients (≥18 years) diagnosed with vitiligo, treated at participating Italian dermatology centers. No intervention is administered; data are collected retrospectively from medical records.
  • Arm: Hidradenitis Suppurativa Cohort
    Adult patients (≥18 years) diagnosed with hidradenitis suppurativa, treated with systemic conventional and/or biologic therapies at participating Italian dermatology centers. No intervention is administered; data are collected retrospectively from medical records

Primary Outcome Measure

Patient Distribution by Disease Type [ Time Frame: January 2016 to December 2025 ]

Central Contacts

Find similar trials

Nationwide
Atopic dermatitis / eczema trialsHidradenitis suppurativa trialsPsoriasis trialsDermatology trialsRheumatology trialsAutoimmune disease trials

Related Studies